An experimental vaccine from Merck & Co Inc designed to protect women against a virus that causes cervical cancer has proved effective for up to five years, researchers said on Wednesday. Women given Gardasil, which Merck is developing with France’s Sanofi-Aventis, experienced no cases of cervical and external genital lesions, the precursors of cancer, scientists told a medical meeting in Paris.
